Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > 98th Annual American Urological Association Meeting
View:
Post by Eoganacht on Oct 17, 2022 5:45pm

98th Annual American Urological Association Meeting

Looks like Dr. McFarland may be collaborating on something new....

98th Annual Meeting
Western Section
Grand Hyatt Kauai Hawaii
 
SCIENTIFIC PROGRAM SUNDAY, OCTOBER 30, 2022
POSTER SESSION 1 - Grand Ballroom
Prostate Cancer

Novel X-Ray Activated Photodynamic (radioPDT) Nanoparticles For Prostate Cancer (PCa) Therapy
 
Ronald B. Moore, MD, PhD, FRCSC, Deepak Dinakaran, MD, PhD, FRCPC,
Abdul Azad, PhD, Hua Chen, PhD, Melinda Wuest, PhD, David Murray, PhD,
Sherri McFarland, PhD, John D. Lewis, PhD, Nawaid Usmani, MD, Ravin
Narian, PhD: Edmonton, AB, Canada, Arlington, TX.
Comment by langosta on Oct 17, 2022 7:22pm
6 days at the Grand Hyatt Kauai resort, Hawaii. Running thru the program book it looks like one gigantic bash. Didn't think there were that many MD's in North America.  Oh, and don't forget to bring your spouses or relevant other. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250